Skip to main content

SuperNova Diagnostics, Concile Reach European Co-marketing Deal

NEW YORK (GenomeWeb News) – Point-of-care firm SuperNova Diagnostics today announced a co-marketing deal with Concile for a test that assesses "various deficiencies" relating to wellness and chronic diseases.

The terms of the deal gives Concile, a German diagnostic development and distribution firm, the rights to co-market SuperNova's test in Europe. SuperNova will develop and manufacture the test, secure regulatory approvals, and co-market it.

Concile will provide SuperNova upfront payments, milestone development payments, and share revenues for sales within the European Union. SuperNova retains all marketing rights outside of the EU, it said.

Neil Campbell, president and CEO of SuperNova, said in a statement, "The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets."

Financial terms were not disclosed.

Headquartered in German Town, Md., SuperNova is a development stage firm whose main technology is a nanochemistry-based DNA amplification method it calls AmpCrystal that achieves "ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements," it said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.